Answers are grounded in this paper and cite their sources.
PURPOSE: Symptomatic vitreous opacities (floaters) are common and can significantly impair vision and quality of life. While vitrectomy is effective for opacities, it is invasive and carries substantial risks. Neodymium-doped yttrium aluminum garnet (Nd: YAG) laser vitreolysis is a less invasive outpatient procedure that may alleviate floater symptoms with fewer risks, but its overall efficacy and safety have not been firmly established. This systematic review and meta-analysis evaluated the efficacy and safety of Nd: YAG vitreolysis for symptomatic vitreous opacities. METHODS: A comprehensive literature search was conducted on September 10th, 2025 using PubMed, Embase, and Scopus to identify studies on Nd: YAG vitreolysis. Studies evaluating Nd: YAG laser vitreolysis for symptomatic vitreous opacities and reporting at least one of the following outcomes: patient reported symptomatic improvement, visual function questionnaire (VFQ) scores, contrast sensitivity, objective imaging changes, or complications were included. RESULTS: Fifteen studies comprising 814 treated eyes and 24 sham-treated eyes were met inclusion. Patients reporting symptomatic improvement following Nd: YAG vitreolysis was 85% (95% confidence interval [CI], 0.69-0.93), with substantial heterogeneity (I² = 84%). In two randomized trials, symptom improvement was more likely with Nd: YAG vitreolysis compared with sham laser, although not significant (risk ratio 5.41, p = 0.08). VFQ-25 scores improved by an average of 11 points (p < 0.01; I² = 90%). Overall contrast sensitivity did not significantly change; however, sensitivity analysis excluding one outlier study demonstrated a modest improvement (mean difference 0.89 log units, p < 0.0001). Objective imaging demonstrated floater reduction in 95% of treated eyes (95% CI, 0.91-0.98). No retinal tears or detachments were reported. Intraocular pressure elevation and retinal hemorrhage occurred in < 1% of eyes. CONCLUSION: These findings suggest that Nd: YAG vitreolysis may provide symptomatic benefit in carefully selected patients. However, the certainty of the available evidence is very low, and the results should be interpreted cautiously. Larger controlled studies with objective, quantitative outcome measures are needed to confirm long-term efficacy and define its role relative to vitrectomy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: